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LETTER TO EDITOR
Radionuclide molecular imaging of abdominal aortic
aneurysms for risk stratification and non-invasive therapy
assessment
Dear Editor,
In this letter, we explore the potential role of
radionuclide-based molecular imaging modalities, such as
positron emission tomography (PET) and single-photon
emission computed tomography (SPECT), in evaluating
abdominal aortic aneurysms (AAA). We further discuss
how the developments of promising radiotracers in com-
bination with ultra-sensitive PET and SPECT scanners
may enable the assessment of AAA formation and pro-
gression and consequently patient risk stratification and
therapeutic interventions.
AAA is an asymptomatic, irreversible, focal enlarge-
ment of the abdominal aorta proceeding to rupture and
eventually resulting in patient death. Patients with early-
stage AAA do not exhibit evident signs or symptoms;
hence,AAA is typically diagnosed during incidental health
assessments or through dedicated screening programmes,
such as those implemented in the USA, the UK and Swe-
den. Although many studies are conducted to identify
more reliable and informative risk factors of AAA rup-
ture, aortic size is the only marker utilised in clinical prac-
tice, with elective repair offered to prevent rupture once an
AAA enlarges to the intervention threshold of 5.5 cm. The
aortic diameter is a straightforward and convenient param-
eter to extract using ultrasound scanning (USS) but may
not consistently correlate with prognosis, as large AAA
may remain intact, while small AAA may rupture.1
Much of our knowledge of human AAA pathology
stems from aortic tissue obtained during surgery (i.e., late-
stage disease); therefore, theories based on findings corre-
sponding to these tissues may not accurately reflect early-
stage disease pathology, when an effective pharmacologi-
cal treatment may be offered. Indeed, one of the most sig-
nificant barriers to overcoming late-stage detection ofAAA
is the ability to detect early-stage molecular mechanisms
that precede physical disease manifestation. Patient man-
agement can be complicated to navigate based solely on
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the risk of AAA rupture as predicted using USS for aor-
tic diameter measurements; in this case, molecular infor-
mation yielded by PET and SPECT may improve the man-
agement and treatment approaches for AAA by provid-
ing more comprehensive information on the molecular
processes occurring within the aortic wall that drive an
aneurysm towards growth and rupture as opposed to sta-
bility. These molecular-level data make PET and SPECT
imaging attractive tools for the purposes of early risk strat-
ification and the assessment of responses to effective low-
risk non-invasive therapeutic interventions as adjuncts to
USS-based screening and surveillance.
Basic research in AAA pathobiology continues to
generate important preclinical data and novel imaging
approaches to support clinical advances. Undoubtedly,
the establishment of reliable and unequivocal radiotrac-
ers remains the ultimate objective of any radionuclide-
based molecular imaging study. The widely used PET
radiotracer [18F]fluorodeoxyglucose ([18F]FDG) has been
shown to correlate with inflammatory markers in AAA
(Figure 1); however, its uptake exhibits inconsistent corre-
lations with pathological and clinical features of AAA.2–4
Thus, alternative radiotracers may be more useful as indi-
cators of molecular events, with implications for more
precise AAA risk stratification and personalised inter-
ventions. For example, [18F]- sodium fluoride ([18F]NaF)
uptake is increased prior to pronounced aortic expansion
in the angiotensin II-induced AAA murine model, reflect-
ing microcalcification, which may indicate an alternative
biological process that can offer a surrogate signal of an
effective therapy.5 Moreover, [18F]NaF localises in regions
of microcalcification in patients with asymptomatic AAA,
acting as a susceptibility marker of aneurysm growth
and rupture and yielding proof-of-concept data for the
practicability of a PET radiotracer other than [18F]FDG
for risk stratification in patients with AAA (Figure 2).6
Meanwhile, in the angiotensin II-induced AAA mouse
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F IGURE 1 In vivo imaging and structural stress of abdominal aortic aneurysms (AAA). Sagittal-view (A) contrast-enhanced CT and (B)
[18F]FDG PET, with (C) structural stress plotted on 3D geometry. Transverse-view (D) contrast-enhanced CT and (E) [18F]FDG PET, with (F)
structural stress plotted on the transverse plane.13 Figure license: Huang et al., 2016. High structural stress andpresence of intraluminal
thrombus predict abdominal aortic aneurysm 18F-FDGuptake. This article is distributed under the terms of the Creative
CommonsAttribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Abbreviations: AAA, abdominal aortic aneurysm; CT, computed tomography; [18F]FDG, [18F]fluorodeoxyglucose; PET, positron emission
tomography.
model, [18F]fluorothymidine demonstrates greater uptake
in early-stage AAA than in late-stage AAA, reflecting
an early period of proliferative activity in AAA forma-
tion and potentially growth, opening up the potential
for anti-proliferative therapies that may be administered
early in the disease course (Figure 3).7 In the porcine
pancreatic elastase-induced AAA murine model, early-
stage [64Cu]DOTA-ECL1i uptake, which reflects binding to
chemokine receptor 2, may facilitate rupture prediction.8
[18F]fluoromethylcholine, which is typically utilised in
prostate cancer staging to identify choline uptake, may
also be useful to identify concurrent AAA in patients
with prostate cancer.9 Regarding the prospect of SPECT,
RP805, a [99mTc]-labelled radiotracer that targets matrix
metalloproteinases (MMPs), has been used to demon-
strate that MMP-targeted SPECT may indicate aortic wall
inflammation and help predict expansion or rupture in
AAA.10 Furthermore, a novel pan-MMP tracer called
RYM1 has successfully demonstrated the specific detec-
tion of MMPs and inflammatory activity in AAA.11 Ulti-
mately, with clinical implementation, the findings of these
radiotracers may perhaps replace the use of [18F]FDG
uptake and supplement classical clinical parameters, such
as aneurysm diameter, since AAA growth—and conse-
quently rupture—is implied to follow a non-linear and
unpredictable trend. As PET and SPECT are currently used
in the clinic for non-AAA applications, further research
on these molecular imaging modalities for patients with
AAA has functional practicality for rapid clinical transla-
tion compared to the process of translating entirely novel
technologies to the clinic.
The road ahead for molecular imaging of AAA may be
intricate, and the smooth translation of positive preclinical
findings to the clinic remains a critical aim. The key obsta-
cle to implementing SPECT for AAA imaging in the clinic
lies in the relatively poorer spatial resolution of clinical
SPECT scanners than that of clinical PET scanners. How-
ever, if a SPECT radiotracer provides substantially valu-
able information, a dedicated redesign of collimators for
AAAmay enable higher-resolution clinical SPECT. Mean-
while, in addition to the extensive range of PET radiotrac-
ers already available in the market, the development of
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F IGURE 2 Ex vivo [18F]NaF micro-PET/CT images and
histology of aortic wall from (A) a patient without an aneurysm at
post-mortem and (B) a patient during open abdominal aortic
aneurysm (AAA) repair. Regions of interest (dashed circle) of
[18F]NaF uptake demonstrate (B1) atheromatous disease with
necrosis (haematoxylin and eosin stain, magnification × 100) and
(B2) calcification (black, Von Kossa stain, magnification × 200) in
the AAA tissue that is not apparent in the control aorta (A1, A2).6
Figure license: Forsythe et al., 2018. 18 F-sodiumfluoride uptake in
abdominal aortic aneurysms: The SoFIA 3 study. Thisarticle is
distributed under the terms of the Creative Commons Attribution
4.0International License
(https://creativecommons.org/licenses/by/4.0/).
Abbreviations: AAA, abdominal aortic aneurysm; [18F]NaF,
[18F]-sodium fluoride; PET/CT, positron emission
tomography/computed tomography.
PET scanners with a substantially longer axial field of view
(4–8 times longer than that of the currently most com-
monly available PET scanners) offers a unique opportu-
nity in accelerating the translation of new radiotracers in
the clinic.12 Particularly, the unprecedentedly high image
quality and resolution combined with the potential for
F IGURE 3 Representative coronal-view static [18F]FLT
PET/CT images. White arrows indicate abdominal aortic location
(short arrow, saline control; long arrow, abdominal aortic aneurysm
[AAA]).7 Figure license: Gandhi et al., 2019. Cell proliferation
detectedusing [18F]FLT PET/CT as an early marker of abdominal
aorticaneurysm. This article is distributed under the terms of the
Creative CommonsAttribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/).
Abbreviations: [18F]FLT, [18F]fluorothymidine; PET/CT, positron
emission tomography/computed tomography.
substantial reduction in the injected radioactive dose to
patients with suspected AAA will enable dynamic imag-
ing as a powerful and sensitive tool to obtain quantitative
and reproducible kinetic information that may help iden-
tify the disease at earlier stages and increase the efficacy
of non-invasive therapeutic interventions for patients with
AAA.
In conclusion, many aspects of AAA evolution remain
poorly understood. Considering the seemingly complex
heterogeneity of AAA and involvement of numerous
contributory factors, anatomical and molecular imaging
modalities must be considered supplementary tools in
their role in AAA management. Importantly, the strength
of radionuclide-based molecular imaging is reflected in
its power to shed light on the molecular evolution of
AAA, which may guide the necessity for surgical repair
or response to pharmacological therapies before the dis-
ease progresses to a severe and irreversible stage. To facili-
tate AAA risk stratification, the quest to identify the most
appropriate radiotracers is an essential path towards reduc-
ing patient morbidity and identifying alternative therapies
that are potentially more efficient and economical than
surgical interventions.
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